Rituximab

Rituximab
Monoclonal antibody
Type	Whole antibody
Source	Endrika:Infobox drug/mab source
Target	CD20
Clinical data
Trade names	Rituxan, MabThera, Truxima, others
Anarana hafa	Rituximab-abbs, rituximab-pvvr
AHFS/Drugs.com	Monograph
MedlinePlus	a607038
[[Regulation of therapeutic goods \|Endrika:Engvar data]]	US DailyMed: Rituximab;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous infusion
Drug class	Monoclonal antibody
Sata ara-dalàna
Sata ara-dalàna	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	100% (IV)
Elimination half-life	30 to 400 hours (varies by dose and length of treatment)
Excretion	Uncertain: may undergo phagocytosis and catabolism in RES
Identifiers
CompTox Dashboard (EPA)	DTXSID5040910Erreur de script : le module a renvoyé une valeur de type nil. Il est supposé renvoyer un tableau d’exportations.;
ECHA InfoCard	100.224.382Erreur de script : le module a renvoyé une valeur de type nil. Il est supposé renvoyer un tableau d’exportations.
Angon-drakitra simika sy ara-batana
Raikipohy	C6416H9874N1688O1987S44
Molar mass	Error in {{val}}: parameter 1 is not a valid number. g·mol−1
	(what is this?) (verify)

Hadisoam-panehoan-kevitra: mpamaritra "<" tsy fantatra.Hadisoam-panehoan-kevitra: mpamaritra "<" tsy fantatra.Hadisoam-panehoan-kevitra: mpamaritra "<" tsy fantatra.Ny Rituximab, amidy amin’ny anarana marika Rituxan sy anarana hafa, dia fanafody ampiasaina amin’ny fitsaboana aretina autoimmune sasany sy karazana homamiadana. [1]

Izy io dia ampiasaina amin’ny fitsaboana ny lymphoma tsy Hodgkin, leukemia lymphocytique mitaiza, arthritis rheumatoid, granulomatosis miaraka amin’ny polyangiitis, purpura thrombocytopenic idiopathic, pemphigus vulgaris, myasthenia gravis, ary fery mucocutaneous mifandray amin’ny Epstein–Barr virus. [1][2][3][4]

Omena amin’ny alalan’ny tsindrona miadana ao anaty lalan-drà izy io. [1] Amin’ny toe-javatra sasany dia mety averina isaky ny 6 volana ny fitsaboana, arakaraka ny aretina tsaboina. [5]

Ny voka-dratsiny mahazatra dia mety ahitana mangidihidy, mangidihidy, tosidra ambany, ary sempotra.^[3] Anisan'ny voka-dratsy hafa koa ny fihetsehan'ny hepatita B indray amin'ireo efa voan'ny aretina, ny leukoencephalopathie multifocal miharatsy, ary ny necrolysis epidermal misy poizina.^[3]^[4] Tsy mazava raha azo antoka ho an'ny zaza ny fampiasana azy mandritra ny fitondrana vohoka.^[3] Amporisihina ny fisorohana mahomby ny fitondrana vohoka mandritra ny fitsaboana sy mandritra ny herintaona aorian'izany.^[5] Rituximab dia antibody monoklonal chimeric manohitra ny proteinina CD20, izay hita indrindra eo amin'ny velaran'ny sela B ao amin'ny hery fiarovana.^[6] Rehefa mifamatotra amin'ity proteinina ity izy dia miteraka fahafatesan'ny sela.^[3]

Ny Rituximab dia nekena ho fanafody ampiasaina ara-pitsaboana tamin’ny taona 1997. [4] Tafiditra ao anatin’ny Lisitry ny fanafody tena ilaina an’ny Fikambanana Iraisam-pirenena Momba ny Fahasalamana izy io. [5]

Eo amin’ny vidiny, ny ambongadiny tany amin’ny firenena an-dalam-pandrosoana tamin’ny taona 2014 dia teo anelanelan’ny 148 ka hatramin’ny 496 dolara amerikana isaky ny 100 mg. [6] Any Royaume-Uni, ny vidin’ny tavoahangy 100 mg ho an’ny NHS dia manodidina ny £150 tamin’ny taona 2021. [3] Any Etazonia kosa, dia manodidina ny $705 isaky ny 100 mg izany tamin’ny taona 2014. [7]

Ho an’ny fitsaboana sasany, toy ny aretin’ny tonon-taolana, ny fitsaboana mahazatra (1 000 mg amin’ny tsindrona anaty lalan-drà, atao isaky ny 2 herinandro) dia mety mahatratra eo amin’ny $14 000 isam-bolana any Etazonia tamin’ny taona 2014. [7]

Tapitra tamin’ny taona 2016 ny patanty amin’ny Rituximab, ka efa nisy biosimilar maro novolavolaina sy nampidirina eny an-tsena. [8]

References

↑ Drugs.com International brand names for rituximab Endrika:Webarchive Page accessed 1 April 2016
↑ "Rituximab Use During Pregnancy". Drugs.com. 16 December 2019. Archived from the original on 30 August 2019. Retrieved 2 February 2020. Endrika:Webarchive
1 2 3 4 "Rituximab". The American Society of Health-System Pharmacists. Archived from the original on 27 March 2016. Retrieved 8 December 2016.
↑ "Boxed Warning and new recommendations to decrease risk of hepatitis B". U.S. Food and Drug Administration (FDA). 13 January 2017. Archived from the original on 3 February 2020. Retrieved 2 February 2020.
↑ (September 2021 - March 2022) “8. Immune system and malignant disease”, British National Formulary (BNF), 82, London: BMJ Group and the Pharmaceutical Press, 933-934.
↑ Bosch, Xavier (2013). Drugs Targeting B-Cells in Autoimmune Diseases (in en). Springer Science & Business Media, 1–4.

[generic-1] Drugs.com International brand names for rituximab Endrika:Webarchive Page accessed 1 April 2016

[Drugs.com_pregnancy-2] "Rituximab Use During Pregnancy". Drugs.com. 16 December 2019. Archived from the original on 30 August 2019. Retrieved 2 February 2020. Endrika:Webarchive

[AHFS2016-3] 1 2 3 4 "Rituximab". The American Society of Health-System Pharmacists. Archived from the original on 27 March 2016. Retrieved 8 December 2016.

[4] "Boxed Warning and new recommendations to decrease risk of hepatitis B". U.S. Food and Drug Administration (FDA). 13 January 2017. Archived from the original on 3 February 2020. Retrieved 2 February 2020.

[BNF82-5] (September 2021 - March 2022) “8. Immune system and malignant disease”, British National Formulary (BNF), 82, London: BMJ Group and the Pharmaceutical Press, 933-934.

[Bos2013-6] Bosch, Xavier (2013). Drugs Targeting B-Cells in Autoimmune Diseases (in en). Springer Science & Business Media, 1–4.

[1]

[2]

[3]

[4]

[5]

[6]